

**UPDATE ON STALLERGENES GREER MANUFACTURING AND DISTRIBUTION ACTIVITIES:**

- **PRODUCT RECALL: ANALYSES SHOW PRODUCT COMPLIANCE WITH REQUIRED SPECIFICATIONS**
- **MORE THAN 250,000 TREATMENTS DELIVERED SINCE THE RESTART OF MANUFACTURING AND DISTRIBUTION**

**DATE: May 27, 2016**

London (UK) - Stallergenes Greer plc (the “Company”) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today provided an update on activities from its Antony, France site following the resumption of manufacturing and distribution activities on 10 March 2016.

As part of the Named Patient Product (NPP) voluntary recall related to the implementation of the ERP system, quality analyses were conducted using a representative sample of returned products. To date, results from these analyses show that the allergen content of the product vials complies with required specifications.

Furthermore, the Company’s “RESTART” plan, which is designed to regain the Company’s global leadership by focusing on production, logistics and commercial capabilities in the EU/International region, helped resume product delivery to patients with an average lead time of two weeks. More than 250,000 treatments have been delivered since the restart, and the Company is able to meet patient demand for the most prevalent allergens.

*“The results of NPP testing validates our confidence in the quality of our products,”* said Michele Antonelli, Stallergenes Greer Executive Vice President, Europe and Rest of the World. *“I am very pleased that we are able to meet the needs of patients and physicians once again with the help of our RESTART plan and we will continue to ensure high quality standards – both in our products and technical operations capabilities. The health and safety of patients has always been and remains our top priority”.*

Learn more about our product availability on our website:

<http://stallergenesgreer.com/product-update>

## ABOUT STALLERGENES GREER PLC

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

### Trading information:

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification: 4577

Market: Euronext Paris regulated market

Additional information is available at <http://www.stallergenesgreer.com>

*This document (including information incorporated by reference in this document), oral statements made and other information published by the Company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe", "expects", "project", "estimated", "forecast", "should", "plan", "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in the Company's 2015 annual report published on 29 April 2016 on the Company's website ([www.stallergenesgreer.com](http://www.stallergenesgreer.com)). Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.*

### Contacts:

#### Investor and analyst relations

Peter Bühler

Chief Financial Officer

Tel: +33 1 55 59 23 22

Email: [investorrelations@aresallergyco.com](mailto:investorrelations@aresallergyco.com)

#### Media relations

Lise Lemonnier

Head of Global Communications

Tel: + 33 1 55 59 20 96

Email: [llemonnier@stallergenes.com](mailto:llemonnier@stallergenes.com)

#### Investor relations agency

FTI Consulting

Arnaud de Cheffontaines

Tel: +33 1 47 03 69 48

Email:

[arnaud.decheffontaines@fticonsulting.com](mailto:arnaud.decheffontaines@fticonsulting.com)

#### Media relations agency

Havas Worldwide Paris

Jean-Baptiste Froville

Tel: +33 1 58 47 95 39

Email: [jean-baptiste.froville@havasww.com](mailto:jean-baptiste.froville@havasww.com)